Screener
Axogen AXGN Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Axogen in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Axogen’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000805928-26-000094
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Net cash provided by financing activities | 63,702 | 3,539 |
| Net increase (decrease) in cash and cash equivalents, and restricted cash | 57,024 | (7,518) |
| Cash and cash equivalents, and restricted cash, beginning of period | 39,548 | 33,554 |
| Cash and cash equivalents, and restricted cash, end of period | $96,572 | $26,036 |
| Supplemental disclosures of cash flow activity: | ||
| Cash paid for interest | $627 | $3,559 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Acquisition of property and equipment change in accounts payable and accrued expenses | $95 | $132 |
ITEM 1 — FINANCIAL STATEMENTS
FAQ
- What is Axogen's cash & equivalents?
- Axogen (AXGN) reported cash & equivalents of $96.57M in Q2 2026.
- How has Axogen's cash & equivalents changed year-over-year?
- Axogen's cash & equivalents increased by 270.9% year-over-year, from $26.04M to $96.57M.
- What is the long-term trend for Axogen's cash & equivalents?
- Over 5 years (2020 to 2025), Axogen's cash & equivalents has grown at a -6.6% compound annual growth rate (CAGR), from $55.61M to $39.55M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Axogen's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude